Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.

Abstract

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown etiology. In several randomized clinical trials, and in the clinical practice, pirfenidone is used to effectively and safely treat IPF. However, sometimes it is difficult to use the dose of pirfenidone used in clinical trials. This study evaluated the effects of low-dose pirfenidone on IPF disease progression and patient survival in the real-world.

METHODS:

This retrospective, observational study enrolled IPF patients seen at the time of diagnosis at a single center from 2008 to 2018. Longitudinal clinical and laboratory data were prospectively collected. We compared the clinical characteristics, survival, and pulmonary function decline between patients treated and untreated with various dose of pirfenidone.

RESULTS:

Of 295 IPF patients, 100 (33.9%) received pirfenidone and 195 (66.1%) received no antifibrotic agent. Of the 100 patients who received pirfenidone, 24 (24%), 50 (50%), and 26 (26%), respectively, were given 600, 1200, and 1800 mg pirfenidone daily. The mean survival time was 57.03 ± 3.90 months in the no-antifibrotic drug group and 73.26 ± 7.87 months in the pirfenidone-treated group (p = 0.027). In the unadjusted analysis, the survival of the patients given pirfenidone was significantly better (hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.48-0.99, p = 0.04). After adjusting for age, gender, body mass index, and the GAP score [based on gender (G), age (A), and two physiological lung parameters (P)], survival remained better in the patients given pirfenidone (HR = 0.56, 95% CI: 0.37-0.85, p = 0.006). In terms of pulmonary function, the decreases in forced vital capacity (%), forced expiratory volume in 1 s (%) and the diffusing capacity of lung for carbon monoxide (%) were significantly smaller (p = 0.000, p = 0.001, and p = 0.007, respectively) in patients given pirfenidone.

CONCLUSIONS:

Low-dose pirfenidone provided beneficial effects on survival and pulmonary function decline in the real-world practice.

• Authors: Eung Gu Lee, Tae-Hee Lee, Yujin Hong, Jiwon Ryoo, Jung Won Heo, Bo Mi Gil, Hye Seon Kang, Soon Seog Kwon, Yong Hyun Kim
• Journal: PloS one (PLoS One) Vol. 16 Issue 12 Pg. e0261684 ( 2021) ISSN: 1932-6203 [Electronic] United States
• PMID: 34941933 (Publication Type: Journal Article, Observational Study)

Chemical References

• Pyridones
• pirfenidone

Topics

• Age Factors
• Aged
• Aged, 80 and over
• Body Mass Index
• Disease-Free Survival
• Female
• Humans
• Idiopathic Pulmonary Fibrosis (drug therapy, mortality, physiopathology)
• Male
• Middle Aged
• Pyridones (administration & dosage)
• Respiratory Function Tests
• Retrospective Studies
• Risk Factors
• Survival Rate